1 Department of Obstetrics and Gynaecology, University of Edinburgh, 37 Chalmers Street, Edinburgh, 2 Department of Obstetrics and Gynaecology, University of Glasgow, Glasgow and 3 School of Biological and Molecular Sciences, Oxford Brookes University, Oxford, UK
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Key words: fetal membranes/inhibin/labour/placenta/pregnancy/trophoblast
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
From in-vitro studies it appears that inhibins are involved in the paracrine regulation of prostaglandin, human chorionic gonadotrophin (HCG) and progesterone release (Petraglia et al., 1989; Petraglia et al., 1993
; Qu and Thomas 1995
), but how the different inhibin isoforms are involved in the maintenance of pregnancy and subsequent initiation and maintenance of labour is unclear. Measurement of inhibins has proved difficult due to the lack of selectivity of the
-subunit-directed immunoassays, which cannot measure the bioactive dimeric isoforms and are confounded by the presence of high concentrations of free
-subunit isoforms. Furthermore, both immuno- and bioassays can be affected by the presence of activins and the activin/inhibin binding protein follistatin. Specific assays have been developed to identify the two dimeric inhibins A and B (Groome et al., 1994
, 1996
) and inhibin isoforms containing pro and
C forms which are predominantly free
-subunit (Groome et al., 1995
; Robertson et al., 1997
). In this study we have measured the dimeric and
-subunit forms of inhibin in the different compartments of pregnancy at term before and at labour. We have identified using in-vitro techniques the principal tissues that secrete inhibins within the uterus. Our findings have revealed that inhibin production is tissue-dependent with directional secretion, resulting in the different bioactive isoforms secreted into different compartments in late gestation. These findings are important in elucidating the regulation and potential roles of the different inhibin isoforms for the paracrine and endocrine control of pregnancy and parturition.
![]() |
Materials and methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Explant tissue culture
Explants of tissues were cultured as described previously by this laboratory (Brennand et al., 1995). Discs of amnion (12 mm diameter; wet weight 1020 mg) and chorion laeve with adherent decidua (9 mm diameter; 1525 mg) were prepared using a cork borer, and pieces of villous placental tissue (collected from the middle of a central cotyledon; 2030 mg) or decidua (2030 mg) from the maternal aspect by curettage were placed on absorbent capillary matting. Tissues were maintained in culture medium (RPMI1640; Life Technologies Ltd, Paisley, UK) supplemented with 10% fetal calf serum (Life Technologies) plus antibiotics in a water saturated air/5% CO2 atmosphere at 37°C. After 24 h, culture medium was collected and stored at 20°C prior to immunoassay.
Dual perfusion of placental cotyledon
The in-vitro isolated dual perfused human placental cotyledon was used, as described previously (Schneider et al., 1972) with minor modifications (Benediktsson et al., 1997
). Within 15 min of delivery, a peripheral intact cotyledon with parallel chorionic artery and vein and also the maternal lacunae were cannulated and perfused with Krebs' solution, which was supplemented with dextran (20 g/l; 74 kDa) in the fetal perfusate. To mimic partial pressures in vivo, the solutions used to perfuse the maternal and fetal circulations were gassed with 95% O2/5% CO2 and 95% N2/5% CO2, respectively. The cotyledon was perfused for 40 min to flush out residual blood and allow circulatory perfusion pressures to stabilize. Perfusates were not recycled. Samples (10 min) were collected after this equilibration period and stored at 20°C prior to assay. Viability and integrity of each preparation was assessed by establishing (i) the input perfusion rate in both fetal (6 ml/min) and maternal (10 ml/min) circuits equalled outflows, (ii) there was adequate exchange of O2 from the maternal to fetal circuits (step-up of pressure from <40 to >70 mmHg on fetal side), (iii) at the end of the experiment, the fetal vasculature responded to a bolus of noradrenaline (20 mg; Sigma), (iv) lactate concentrations remained within the normal low range (<2 mmol/l; Benediktsson et al., 1997) throughout the sampling period, and (v) there were no significant morphological changes on subsequent histological examination.
Immunoassays for inhibin isoforms
The inhibin assays used were two-site enzyme-linked immunosorbent assay (ELISA). These assays have been previously described, characterized and their specificities and cross-reactivities detailed (Groome et al., 1994, 1995
, 1996
) and were performed with minor modifications (Riley et al., 1996
; Wallace et al., 1997
). Immunoassay plates (96-well; Nunc Maxisort, Life Technologies Ltd) were coated passively with specific mouse monoclonal capture antibodies raised to peptide sequences of the inhibin ßA (antibody E4) and ßB (C5) subunits and the pro- portion of the inhibin-
subunit (INPRO) which conferred the assay specificity to inhibin A-, inhibin B- and pro- and
C-containing inhibin immunoreactivity. Plates were dried using a dry coating reagent and stored at 4°C (diluted 1:1 with H2O; Bionostics Ltd, Wyboston, UK). For the inhibin A and B assays samples and standards were diluted as appropriate with fetal calf serum, incubated in sodium dodecyl sulphate (2% final volume) for 3 min at 100°C which improves the signal and removes false positive results. Samples were then pretreated with H2O2 (1% final volume) for 30 min at 23°C, which increases antibody reactivity by modification of the ß-subunit epitopes (Knight and Muttukrishna, 1994
), prior to adding to the appropriate ELISA plate. In the assay for pro-
C inhibin immunoreactivity all dilutions were performed in triton assay diluent and samples were applied directly to the plate without pretreatment (Groome et al., 1995
).
The standard used for the inhibin A and inhibin B assay is a partially immunopurified inhibin standard from human follicular fluid calibrated against recombinant 32 kDa human inhibin A or inhibin B (Genentech, CA, USA) with results expressed in terms of this recombinant form. These assays have been validated for amniotic fluid (Riley et al., 1996; Wallace et al., 1997
) and plasma samples (Groome et al., 1994
; Robertson et al., 1997
). For the assay for inhibin forms containing pro- and
C immunoreactivity the capture antibody (INPRO) was raised against a sequence of the pro-
C subunit, with a highly purified preparation of pro-
C inhibin as standard, as described previously (Groome et al., 1995
). The pro-
C assay predominantly measures the 36 and 29 kDa forms (Robertson et al., 1997
), although it may possess some cross-reactivity with larger forms of dimeric inhibin containing the
-subunit pro sequence as indicated by immunoblot (Groome et al., 1995
). All assays utilized the same detection antibody (R1), the Fab fraction raised against the N-terminal region of the 20 kDa inhibin-
subunit which is conjugated to alkaline phosphatase. This alkaline phosphatase activity was detected in the inhibin A and pro-
C inhibin assays by addition of the substrate p-nitrophenylphosphate (Kirkegaard and Perry Laboratories, Gaithersburg, MA, USA), then measuring absorbancy at 405 nm using a microplate reader (Molecular Devices Corp., Menlo Park, CA, USA) with integrated software (Softmax; Molecular Devices), or for inhibin B using an amplification kit (Life Technologies Ltd) and measuring absorbancy at 490 nm. The assay sensitivity, and intra- and inter-plate coefficients of variation were: for inhibin A, 7 pg/ml and 6% and 8%; for inhibin B, 15 pg/ml and 8% and 10%; and for inhibin pro-
C, 3 pg/ml and 4% and 6%, respectively.
Data analysis
All sample sets had a normal distribution and statistical differences were assessed using Student's t-test. Differences were recognized as significant when P < 0.05.
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
|
Fetus: cord serum, fetal urine and expirated lung fluids
The concentrations of inhibin isoforms in cord serum are shown in Figure 2. There were no differences between concentrations of inhibins in cord serum from fetuses of the same sex collected before the onset of labour at elective Caesarean section and after labour, so these groups were combined (Figure 2
). Immunoreactive pro-
C inhibin was present in cord serum from both male (2689 ± 276 pg/ml; mean ± SEM; n = 17) and female (2674 ± 379; n = 13) fetuses at similar concentrations with no significant differences between sexes. These concentrations in cord blood are similar to those present in maternal serum. Inhibin B was only detectable in cord serum from male fetuses (110 ± 11 pg/ml; mean ± SEM; n = 17), but was undetectable in serum collected from females. No dimeric inhibin A was detectable in cord serum from either sex. In fetal urine (n = 8), no inhibin A, inhibin B or pro-
C immunoreactivity were detectable. In fetal lung fluids (n = 4), inhibin A, inhibin B and pro and
C immunoreactive inhibin isoforms were present in similar amounts to those found in the respective matched amniotic fluid sample (data not shown). This is probably not surprising as this fluid is made up principally of amniotic fluid inhaled during fetal breathing movements.
|
|
|
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The predominant source of the inhibin A and inhibin B in amniotic fluid is likely trophoblast of chorion laeve of the fetal membranes. The main sources of amniotic fluid production are via the fetal membranes and fetal urine, with some contribution from the fetal lung (Gilbert and Brace, 1993). Chorion explants secrete similar amounts of inhibin A and B and this is the same pattern of secretion in amniotic fluid. Although no attempt was made to separate adherent decidua from the chorion explants, this presence of trophoblast cells would seem to be the determinant of secretion of dimeric inhibins. This is because decidua parietalis obtained from the myometrial aspect, which contains little contamination by trophoblast cells, only secreted low concentrations of inhibin isoforms. In decidua parietalis, mRNA to the ß-subunit isoforms is expressed and this probably results in mostly activin secretion (Petraglia et al., 1990
, 1997
). There is no secretion of inhibins via the fetal urine. The fetal lung cannot be discounted as a potential source, but lung fluids obtained at first expiration after delivery contained similar concentrations to those found in the amniotic fluid, as would be anticipated, as it largely contains amniotic fluid. The source of immunoreactive pro-
C inhibin isoforms is less easy to define and may be secreted from several sites, including the amnion, chorion laeve and decidua parietalis. The fetus may also be a site of production of pro-
C inhibin, which is present in the fetal circulation although the mechanism of secretion into amniotic fluid is unclear but would probably be via the lung. These results are consistent with findings in the first trimester (Riley et al., 1996
, 1998
) where dimeric inhibins A and B and pro-
C isoforms and activin A are present in extra-embryonic coelomic fluid, with pro-
C but no dimeric inhibin in amniotic fluid. This indicates that the trophoblast layer is the principal site of dimeric inhibin production at this stage. It is only when the amnion fuses to the chorion laeve with the loss of the extra-embryonic coelom, and the amniotic cavity becomes the sole intrauterine compartment, that dimeric inhibins are present in the amniotic fluid and increase with gestation (Wallace et al., 1997
). This unidirectional secretion of inhibin B secretion into the amniotic fluid but not into maternal serum is similar to that of prolactin, which is produced by decidua parietalis but is only present in amniotic fluid (Rosenberg et al., 1980
), demonstrating that protein hormones can be directed into amniotic fluid.
In the maternal circulation, high concentrations of inhibin pro and C and inhibin A are present, with low concentrations of inhibin B. This is in the same range of concentrations as reported previously (Fowler et al., 1998
). The likely site of secretion of inhibin A and inhibin pro-
C is the syncytiotrophoblast of the placenta. Protein and mRNA to
and ßA subunits are localized at this site (Petraglia et al., 1992
; Petraglia, 1997
) and placental trophoblast cells secrete inhibin A (Keelan et al., 1994
; Qu and Thomas, 1995
). This secretion of inhibin A by placenta is unidirectional into maternal blood, whereas inhibin pro-
C is secreted in both directions. The ovary may also remain a source of circulating inhibins at term (Kettel et al., 1991
; Illingworth et al., 1996b
), and also the adrenal gland (Spencer et al., 1992
; Munro et al., 1999
). The chorion laeve of the fetal membranes may contribute to the low concentrations of inhibin B found in the maternal circulation at term.
In the fetal circulation dimeric inhibin B, which is the important isoform in the male (Illingworth et al., 1996a), was detected in cord blood from male but not female fetuses, confirming our previous findings (Wallace et al., 1997
). Immunoreactive inhibin containing pro-
C was present in similar amounts in cord serum from both fetuses of both sexes, although no inhibin A was detectable in cord serum from fetuses of either sex. Our current findings are in agreement with the reports using the non-selective assays for free
-subunit which demonstrated the presence of inhibins in cord serum (Massa et al., 1992
; Billiar et al., 1995
; Rombauts et al., 1996
). Billiar et al. (1995) reported that there was no dimeric inhibin present although their assay was not able to detect inhibin B as detected in this and previous studies (Wallace et al., 1997
). In the fetus, only the steroidogenic tissues of the testis and adrenal gland express the
-subunit mRNA, whereas the mRNA to both the ßA and ßB subunits is expressed in multiple organ systems (Rabinovici et al., 1991
; Jaffe et al., 1993
; Tuuri et al., 1994
), possibly reflecting activin secretion. Therefore the fetal testis, not the adrenal gland, is the likely source of dimeric inhibin B as it is specific to the male fetus. Immunoreactive pro-
C inhibin detected in the fetal circulation may be due, at least in part, to placental secretion as shown by output into this circuit in the perfused placental cotyledon. The fetal adrenal gland also expresses mRNA to inhibin
(Munro et al., 1999
) and may be a source of pro-
C inhibin in cord serum, irrespective of fetal sex.
These studies provide evidence for a decrease in local -subunit production within the fetal membranes at parturition, with the reduction of both inhibin pro-
C and also inhibin A in amniotic fluid at spontaneous delivery. The likely site for this control is the trophoblast cells of chorion laeve, which secrete both bioactive dimeric inhibin isoforms. The placenta secretes only inhibin A in significant amounts into the maternal circulation with no changes at labour. However, the role of inhibins in the regulation of labour is not well defined. They are probably diverse due to their secretion into both maternal circulation with potential for an endocrine role, as well as being local regulators at the feto-maternal interface. Inhibins have a diverse range of functions which are important in the paracrine signalling to initiate labour including control of steroidogenesis (Petraglia et al., 1987
) and peptide hormone and prostaglandin secretion (Petraglia et al., 1993
; Qu and Thomas, 1995
) and monocyte chemotaxis (Petraglia et al., 1991b
). The presence of the novel inhibin receptors (Hertan et al., 1999
) in the uterus remains to be defined, but inhibins may modulate activin action at the level of activin receptors (Martens et al., 1997
) which are expressed by placenta, fetal membranes and decidua (Petraglia et al., 1997
). Local decreases in inhibin A and
-subunit production altering the balance of inhibins and activins may modulate paracrine mechanisms involved in the timing of the onset and for maintaining the cascade of stimuli required for progression to delivery.
![]() |
Acknowledgments |
---|
![]() |
Notes |
---|
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Brennand, J.E., Leask, R., Kelly, R.W. et al. (1995) Changes in prostaglandin synthesis and metabolism associated with labour and the influence of dexamethasone, RU486 and progesterone. Eur. J. Endocrinol., 133, 527533.[ISI][Medline]
Billiar, R.B., Smith, P. and Falcone, T. (1995) Identification of immunoreactive inhibin in human and baboon serum at term as free -subunit. J. Clin. Endocrinol. Metab., 80, 31733179.[Abstract]
De Kretser, D.M., Foulds, L.M., Hancock, M. and Robertson, D.M. (1994) Partial characterisation of inhibin, activin and follistatin in the term human placenta. J. Clin. Endocrinol. Metab., 79, 502507.[Abstract]
Fang, J., Yin, W., Smiley, E. et al. (1996) Molecular cloning of the mouse activin beta E subunit gene. Biochem. Biophys. Res. Commun., 228, 669674.[ISI][Medline]
Fowler, P.A., Evans, L.W., Groome, N.P. et al. (1998) A longitudinal study of maternal serum inhibin-A, inhibin-B, activin-A, activin-AB, pro-C and follistatin during pregnancy. Hum. Reprod., 13, 35303536.[Abstract]
Gilbert, W.M. and Brace, R.A. (1993) Amniotic fluid volume and normal flows to and from the amniotic cavity. Semin. Perinatol., 17, 150157.[ISI][Medline]
Groome, N.P., Illingworth, P.J., O'Brien, M. et al. (1994) Detection of dimeric inhibin throughout the human menstrual cycle by two-site enzyme immunoassay. Clin. Endocrinol., 40, 717723.[ISI][Medline]
Groome, N.P., Illingworth, P.J., O'Brien, M. et al. (1995) Quantification of inhibin pro-C-containing forms in human serum by a new ultrasensitive two-site enzyme-linked immunosorbent assay. J. Clin. Endocrinol. Metab., 80, 29262932.[Abstract]
Groome, N.P., Illingworth, P.J., O'Brien, M. et al. (1996) Inhibin-B: a critical new hormone in the regulation of the female menstrual cycle. J. Clin. Endocrinol. Metab., 81, 14011405.[Abstract]
Hertan, R., Farnworth, P.G., Fitzsimmons, K.L. and Robertson, D.M. (1999) Identification of high affinity binding sites for inhibin on ovine pituitary cells in culture. Endocrinology, 140, 612.
Illingworth, P.J., Groome, N.P., Byrd, W. et al. (1996a) Inhibin-B: a likely candidate for the physiologically important form of inhibin in men. J. Clin. Endocrinol. Metab., 81, 13211325.[Abstract]
Illingworth, P.J., Groome, N.P., Duncan, W.C. et al. (1996b) Measurement of circulating inhibin forms during the establishment of pregnancy. J. Clin. Endocrinol. Metab., 81, 14711475.[Abstract]
Jaffe, R.B., Spencer, S.J. and Rabinovici, J. (1993) Activins and inhibins: gonadal peptides during prenatal development and adult life. Ann. NY Acad. Sci., 687 19.[ISI]
Keelan, J., Song, Y. and France, J.T. (1994) Comparative regulation of inhibin, activin and human chorionic gonadotrophin by placental trophoblast cells in culture. Placenta, 15, 803818.[ISI][Medline]
Knight, P.G. and Muttukrishna, S. (1994) Measurement of dimeric inhibin using a modified two-site immunoradiometric assay specific for oxidised (Met O) inhibin. J. Endocrinol., 141, 417425.[Abstract]
Kettel, L.M., Roseff, S.J., Bangah, M.L. et al. (1991) Circulating levels of inhibin in pregnant women at term: simultaneous disappearance with oestradiol and progesterone after delivery. Clin. Endocrinol., 34, 1923.[ISI][Medline]
Martens, J.W., de Winter, J.P., Timmerman, M.A. et al. (1997) Inhibin interferes with activin signalling at the level of the activin receptor complex in chinese hamster ovary cells. Endocrinology, 138, 29282936.
Massa, G., de Zegher, F. and Vanderschueren-Lodeweyckx, M. (1992) Serum levels of immunoreactive inhibin, FSH and LH in human infants at preterm and term birth. Biol. Neonate, 61, 150155.[ISI][Medline]
Munro, L.M.A., Kennedy, A. and McNicol, A.M. (1999) The expression of inhibin/activin subunits in the human adrenal cortex and its tumours. J. Endocrinol., 161, 341347.
Muttukrishna, S., George, L., Fowler, P.A. et al. (1995) Measurement of serum concentrations of inhibin-A (-ßA dimer) during human pregnancy. Clin. Endocrinol., 42, 391397.[ISI][Medline]
Petraglia, F. (1997) Inhibin, activin and follistatin in the human placenta a new family of regulatory peptides. Placenta, 18, 38.[ISI][Medline]
Petraglia, F., Sawchenko, P., Lim, A.T.W. et al. (1987) Localization, secretion and action of inhibin in placenta. Science, 237, 187189.[ISI][Medline]
Petraglia, F., Vaughan, J. and Vale, W. (1989) Inhibin and activin modulate the release of gonadotropin releasing hormone, human chorionic gonadotropin and progesterone from human placental cells. Proc. Natl Acad. Sci. USA, 86, 51145117.[Abstract]
Petraglia, F., Calza, L., Garuti, G.C. et al. (1990) Presence and synthesis of inhibin subunits in human decidua. J. Clin. Endocrinol. Metab., 71, 487492.[Abstract]
Petraglia, F., Garuti, G.C., Calza, L. et al. (1991a) Inhibin subunit in human placenta: localisation and messenger ribonucleic acid levels during pregnancy. Am. J. Obstet. Gynecol., 165, 750758.[ISI][Medline]
Petraglia, F., Sacerdote, P., Cossarizza, A. et al. (1991b) Inhibin and activin modulate human monocyte chemotaxis and human lymphocyte interferon-gamma production. J. Clin. Endocrinol. Metab., 72, 496502.[Abstract]
Petraglia, F., Woodruff, T.K., Botticelli, G. et al. (1992) Gonadotropin-releasing hormone, inhibin and activin in human placenta: evidence for a common cellular localization. J. Clin. Endocrinol. Metab., 74, 11841188.[Abstract]
Petraglia, F., Anceschi, M.M., Calza, L. et al. (1993) Inhibin and activin in human fetal membranes: evidence for a local effect on prostaglandin release. J. Clin. Endocrinol. Metab., 77, 542548.[Abstract]
Petraglia, F., Di Blasio, A.M., Florio, P. et al. (1997) High levels of fetal membrane activin ßA and activin receptor IIB mRNAs and augmented concentration of amniotic fluid activin A in women in term and preterm labour. J. Endocrinol., 154, 95101.[Abstract]
Qu, J. and Thomas, K. (1995) Inhibin and activin production in human placenta. Endocr. Rev., 16, 485507.[ISI][Medline]
Rabinovici, J., Goldsmith, P.C., Roberts, V.J. et al. (1991) Localisation and secretion of inhibin/activin subunits in the human and subhuman primate fetal gonads. J. Clin. Endocrinol. Metab., 73, 11411149.[Abstract]
Riley, S.C., Wathen, N.C., Chard, T. et al. (1996) Inhibin in extra-embryonic coelomic and amniotic fluids and maternal serum in early pregnancy. Hum. Reprod., 11, 27722776.[Abstract]
Riley, S.C., Balfour, C., Evans, L.W. et al. (1998) Follistatin and activin A in extraembryonic coelomic and amniotic fluids and maternal serum in early pregnancy. Hum. Reprod., 13, 26242628.[Abstract]
Robertson, D.M., Cahir, N., Findlay, J.K. et al. (1997) The biological and immunological characteristics of inhibin A and B forms in human follicular fluid and plasma. J. Clin. Endocrinol. Metab., 82, 889896.
Rombauts, L., Verhoeven, G., Meuleman, C. et al. (1996) Dimeric inhibin A and -subunit immunoreactive material in maternal serum during spontaneous and in vitro fertilization pregnancies. J. Clin. Endocrinol. Metab., 81, 985989.[Abstract]
Rosenberg, S.M., Maslar, I.A. and Riddick, D.H. (1980) Decidual production of prolactin in late gestation: further evidence for a decidual source of amniotic fluid. Am. J. Obstet. Gynecol., 138, 681685.[ISI][Medline]
Schneider, H., Panigel, M. and Dancis, J. (1972) Transfer across the perfused human placenta of antipyrine, sodium and leucine. Am. J. Obstet. Gynecol., 114, 822828.[ISI][Medline]
Spencer, S.J., Rabinovici, J., Mesiano, S. et al. (1992) Activin and inhibin in the human adrenal gland. J. Clin. Invest., 90, 142149.[ISI][Medline]
Tuuri, T., Erämaa, M., Hildén, K. and Ritvos, O. (1994) The tissue distribution of activin ßA- and ßB-subunit and follistatin messenger ribonucleic acids suggests multiple sites of action for the activin-follistatin system during human development. J. Clin. Endocrinol. Metab., 78, 15211524.[Abstract]
Wallace, E.M., Riley, S.C., Crossley, J.A. et al. (1997) Dimeric inhibins in amniotic fluid, maternal serum and fetal serum in human pregnancy. J. Clin. Endocrinol. Metab., 82, 218222.
Submitted on August 23, 1999; accepted on November 19, 1999.